An analysis from clinico-epidemiological data of the principal adverse events from the COX-2 selective NSAID, nimesulide, with particular reference to hepatic injury

Inflammopharmacology

Volumn 6, Issue 3, 1998, Pages 203-221

  Rainsford, K D ^a  

^a SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

Author keywords

COX 2; Nimesulide; NSAID

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; SULINDAC;

ADULT; AGED; ARTHRITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG INDUCED DISEASE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER INJURY; LIVER TOXICITY; MALE; MULTICENTER STUDY; OSTEOARTHRITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

EID: 0031782660     PISSN: 09254692     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10787-998-0020-6     Document Type: Article

References (28)

1. 1. E Magni 1993 The effect of nimesulide on prostanoid formation Drugs 46 1 10 14 7506143 1:CAS:528:DyaK2cXitVyitr4%3D Magni E. The effect of nimesulide on prostanoid formation. Drugs. 1993;46:(1):10–14.
2. 2. IA Tavares PM Bishai A Bennett 1995 Activity of nimesulide on constitutive and inducible cyclooxygenases Arzneim Forsch. 45 II 1 3 Tavares IA, Bishai PM, Bennett A. Activity of nimesulide on constitutive and inducible cyclooxygenases. Arzneim Forsch. 1995;45(II):1–3.
3. 3. R Maffei Facino M Carini G Aldini 1993 Antioxidant activity of nimesulide and its main metabolites Drugs. 46 1 15 21 1:CAS:528:DyaK2cXitVyitr8%3D Maffei Facino R, Carini M, Aldini G. Antioxidant activity of nimesulide and its main metabolites. Drugs. 1993;46:(1):15–21.
4. 4. R Maffei Facino M Carina G Aldini L Saibene R Morelli 1995 Different inhibition of superoxide, hydroxyl and peroxyl radicals by nimesulide and its main metabolite 4-hydroxynimesulide Arzneim Forsch. 45 II 10 17 Maffei Facino R, Carina M, Aldini G, Saibene L, Morelli R. Different inhibition of superoxide, hydroxyl and peroxyl radicals by nimesulide and its main metabolite 4-hydroxynimesulide. Arzneim Forsch. 1995;45(II):10–17.
5. 5. F Dallegri L Ottonello M Bevilacqua 1995 Possible modes of action of nimesulide in controlling neutrophilic inflammation Arzneim Forsch. 45 II 22 4 Dallegri F, Ottonello L, Bevilacqua M. Possible modes of action of nimesulide in controlling neutrophilic inflammation. Arzneim Forsch. 1995;45(II):22–4.
6. 6. ATJ Tool AJ Verhoeven 1995 Inhibition of the production of platelet activating factor and leukotriene B4 in activated neutrophils by nimesulide due to elevation of intracellular cyclic adenosine monophosphate Azneim Forsch. 45 II 18 22 Tool ATJ, Verhoeven AJ. Inhibition of the production of platelet activating factor and leukotriene B4 in activated neutrophils by nimesulide due to elevation of intracellular cyclic adenosine monophosphate. Azneim Forsch. 1995;45(II):18–22.
7. 7. R Davis RN Brogden 1994 Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy Drugs 48 431 54 7527762 1:CAS:528:DyaK2cXmsVCrsbg%3D Davis R, Brogden RN. Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1994;48:431–54.
8. 8. KD Rainsford 1997 Side Effects of Anti-Inflammatory Drugs IV Springer Netherlands Dordrecht Rainsford, KD, ed. Side Effects of Anti-Inflammatory Drugs IV. Dordrecht: Kluwer Academic Publishers; 1997.
9. 9. IA Fussetti E Magni MC Armandola 1993 Tolerability of nimesulide: epidemiological data Drugs 46 1 277 80 10.2165/00003495-199300461-00070 Fussetti IA, Magni E, Armandola MC. Tolerability of nimesulide: epidemiological data. Drugs. 1993; 46:(1):277–80.
10. 10. W Steenbergen Van T Roskams V Desmet 1997 Nimesulide-induced hepatitis: evidence from three cases Gastroenterology. 112 Suppl A1407 A1407 Van Steenbergen W, Roskams T, Desmet V. Nimesulide-induced hepatitis: evidence from three cases. Gastroenterology. 1997;112(Suppl):A1407.
11. 11. JC Grinola L Arias M Rodán L Solá H Bagnula 1998 Hepatotoxidad asociada a la nimesulida. (Revisión de 5 casos.) Arch Med Int (Montevideo) 20 13 18 Grinola JC, Arias L, Rodán M, Solá L, Bagnula H. Hepatotoxidad asociada a la nimesulida. (Revisión de 5 casos.). Arch Med Int (Montevideo). 1998;20:13–18.
12. 12. WM O'Brien 1992 Hepatitis due to non-steroidal anti-inflammatory drugs (NSAIDs) KD Rainsford G-P Velo Side Effects of Anti-inflammatory Drugs 3 Springer Netherlands Lancaster 211 22 O'Brien WM. Hepatitis due to non-steroidal anti-inflammatory drugs (NSAIDs) In: Rainsford KD, Velo G-P, eds. Side Effects of Anti-inflammatory Drugs 3. Lancaster: Kluwer Academic Publishers; 1992:211–22.
13. 13. JR Hannequin M Doffoel G Schmutz 1988 Les hepatites secondaires aux anti-inflammatoires nonsteroidiens recent Rev Rhumatisme 55 983 8 1:STN:280:DyaL1M7os1GmtA%3D%3D Hannequin JR, Doffoel M, Schmutz G. Les hepatites secondaires aux anti-inflammatoires nonsteroidiens recent. Rev Rhumatisme. 1988;55:983–8.
14. 14. UA Boelsterli HJ Zimmermann A Kretz-Rommel 1995 Idiosyncratic liver toxicity of non-steroidal anti-inflammatory drugs: molecular mechanisms and pathology Crit Rev Toxicol. 25 207 35 7576152 1:CAS:528:DyaK2MXms1Sjur4%3D Boelsterli UA, Zimmermann HJ, Kretz-Rommel A. Idiosyncratic liver toxicity of non-steroidal anti-inflammatory drugs: molecular mechanisms and pathology. Crit Rev Toxicol. 1995; 25:207–35.
15. 15. LF Prescott 1992 The hepatotoxicity of non-steroidal anti-inflammatory drugs KD Rainsford G-P Velo Side Effects of Anti-inflammatory Drugs 3 Springer Netherlands Lancaster 176 87 Prescott LF. The hepatotoxicity of non-steroidal anti-inflammatory drugs, In: Rainsford KD, Velo G-P, eds. Side Effects of Anti-inflammatory Drugs 3. Lancaster: Kluwer Academic Publishers; 1992:176–87.
16. 16. KD Rainsford 1994 Diclofenac (Voltaren:Voltarol)-associated hepatotoxicity Inflammopharmacology 2 333 6 10.1007/BF02678598 Rainsford KD. Diclofenac (Voltaren:Voltarol)-associated hepatotoxicity. Inflammopharmacology 1994;2:333–6.
17. 17. HJ Zimmermann 1994 Hepatic injury associated with nonsteroidal anti-inflammatory drugs AJ Lewis DE Furst Nonsteroidal Anti-Inflammatory Drugs. Mechanisms and Clinical Uses 2nd edn. Marcel Dekker New York 171 94 Zimmermann HJ. Hepatic injury associated with nonsteroidal anti-inflammatory drugs. In: Lewis AJ, Furst DE, eds. Nonsteroidal Anti-Inflammatory Drugs. Mechanisms and Clinical Uses, 2nd edn. New York: Marcel Dekker; 1994:171–94.
18. 18. British National Formulary No. 33, March 1997. British Medical Association and Royal Pharmaceutical Society London/Oxford, 1997:180.
19. 19. L Buscarini 1996 Anti-inflammatory analgesics and drugs used in gout MNG Dukes Meyer's Side Effects of Drugs 13th edn. Elsevier Amsterdam 204 64 Buscarini L. Anti-inflammatory analgesics and drugs used in gout. In: Dukes MNG, ed. Meyer's Side Effects of Drugs, 13th edn. Amsterdam: Elsevier; 1996:204–64.
20. 20. KD Rainsford G-P Velo 1987 Side Effects of Anti-Inflammatory Drugs 1. Clinical and Epidemiological Aspects MTP Press Lancaster Rainsford KD, Velo G-P, eds. Side Effects of Anti-Inflammatory Drugs 1. Clinical and Epidemiological Aspects. Lancaster: MTP Press; 1987.
21. 21. KD Rainsford G-P Velo 1992 Side Effects of Anti-inflammatory Drugs 3 Springer Netherlands Lancaster Rainsford KD, Velo G-P, eds. Side Effects of Anti-inflammatory Drugs 3. Lancaster: Kluwer Academic Publishers; 1992.
22. 22. JCP Weber 1984 Epidemiology of adverse reactions to non-steroidal anti-inflammatory drugs KD Rainsford G-P Velo Side-Effects of Anti-Inflammatory/Analgesic Drugs Raven Press New York 1 7 Weber JCP. Epidemiology of adverse reactions to non-steroidal anti-inflammatory drugs. In: Rainsford KD, Velo G-P eds. Side-Effects of Anti-Inflammatory/Analgesic Drugs. New York: Raven Press; 1984:1–7.
23. 23. ME Weinblatt JRP Tesser JH Gilliam 1982 The liver in rheumatic diseases Semin Arth Rheum. 11 399 405 10.1016/0049-0172(82)90027-0 1:STN:280:DyaL383kvF2iuw%3D%3D Weinblatt ME, Tesser JRP, Gilliam JH. The liver in rheumatic diseases. Semin Arth Rheum. 1982;11:399–405.
24. 24. MW Whitehouse KD Rainsford 1977 Side-effects of anti-inflammatory drugs: are they essential or can they be prevented Agents Actions 3 suppl. 171 87 Whitehouse MW, Rainsford KD. Side-effects of anti-inflammatory drugs: are they essential or can they be prevented. Agents Actions. 1977;3(suppl.):171–87.
25. 25. SM Helfgott J Sandberg-Cook D Zakin J Nestler 1990 Diclofenac-associated hepatotoxicity J Am Med Assoc. 264 2660 2 10.1001/jama.264.20.2660 1:STN:280:DyaK3M%2FjvFOntw%3D%3D Helfgott SM, Sandberg-Cook J, Zakin D, Nestler J. Diclofenac-associated hepatotoxicity. J Am Med Assoc. 1990;264:2660–2.
26. 26. BE Wiholm M Myrhed E Ekman 1987 Trends and patterns in adverse drug reactions to non-steroidal anti-inflammatory drugs reported in Sweden KD Rainsford G-P Velo Side Effects of Anti-Inflammatory Drugs. 1. Clinical and Epidemiological Aspects MTP Press Lancaster 55 70 Wiholm BE, Myrhed M, Ekman E. Trends and patterns in adverse drug reactions to non-steroidal anti-inflammatory drugs reported in Sweden. In: Rainsford KD, Velo G-P, eds. Side Effects of Anti-Inflammatory Drugs. 1. Clinical and Epidemiological Aspects. Lancaster: MTP Press; 1987:55–70.
27. 27. H Friis PB Andreasen 1992 Drug-induced hepatic injury: analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987 J Intern Med. 232 133 8 1506809 1:STN:280:DyaK38zntlWltg%3D%3D 10.1111/j.1365-2796.1992.tb00562.x Friis H, Andreasen PB. Drug-induced hepatic injury: analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987. J Intern Med. 1992;232:133–8.
28. 28. LJ Miwa JK Jones A Pathiyal H Hatoum 1997 Value of epidemiologic studies in determining the true incidence of adverse events. The nonsteroidal anti-inflammatory drug story Arch Intern Med. 157 2129 36 9382670 10.1001/archinte.157.18.2129 1:STN:280:DyaK1c%2Fit1WjtQ%3D%3D Miwa LJ, Jones JK, Pathiyal A, Hatoum H. Value of epidemiologic studies in determining the true incidence of adverse events. The nonsteroidal anti-inflammatory drug story. Arch Intern Med. 1997;157:2129–36.